The Medical Advisor

Introduction: The Rise of Metabolic Therapy in Cancer Care The field of oncology is generally based on three treatment areas: medical oncology, radiation oncology, and surgical oncology. However, another area is looming on the horizon, quickly gaining traction as a new and exciting frontier of cancer treatment. Metabolic oncology, also known as cancer metabolism, focuses on how cancer cells use energy and nutrients differently than normal cells. Scientists working in metabolic oncology look for targets in these metabolic processes to create treatments that can specifically attack cancer cells while protecting healthy cells. Leading researchers have discovered innovative ways to prevent diseases from spreading and drastically improve patient outcomes. A groundbreaking approach is emerging in oncology that targets cancer cell metabolism. This innovative strategy targets the unique way cancer cells process energy and nutrients, offering new hope for patients and clinicians alike. As ...

Abstract In 2022, approximately 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide. By 2050, new cases are projected to double, driven by population growth, aging, and increased exposure to risk factors. Up to 40% of cancers may be preventable by addressing lifestyle and environmental risk factors. Numerous nutraceuticals and repurposed drugs exhibit chemoprophylactic properties. Epigallocatechin gallate (EGCG), a polyphenol in green tea, appears to be the most effective agent against multiple cancers, followed by curcumin, a . polyphenol derived from turmeric (Curcuma longa), vitamin D, and omega-3 fatty acids. Using artificial intelligence and leveraging synergistic effects among these compounds, we developed the ROOT 3, ROOT 4, ROOT 5, ROOT 6, and ROOT 9 chemoprophylactic protocols. The mechanistic activity of each nutraceutical is described, along with the estimated risk reduction for the most common types of cancer. These protocols may offer a low-risk an...

Insights from Dr. Paul Marik and Dr. Justus Hope on the hidden drivers of cancer relapse, featuring the revamped CSC Cancer Tree and practical strategies using repurposed drugs and natural compounds. Cancer treatment often succeeds—until it doesn’t. A tumor shrinks. A scan looks clean. The patient goes home hopeful. And then… the cancer returns, sometimes more aggressive than before. The answer lies with a small population of cells that most standard treatments ignore: cancer stem cells (CSCs). These cells not only survive chemotherapy and radiation but adapt and return, driving relapse, metastasis, and mortality.   Dr. Paul Marik and Dr. Justus Hope have collaborated to highlight this critical issue, offering a free guide that explains CSCs, why conventional therapies fail against them, and how safe, affordable repurposed drugs and natural compounds can target them for long-term remission. This guide builds on earlier work, including the CSC Cancer Tree from Dr. Hope's 2020 book,...